- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 14/595 - Gastrines; Cholécystokinines (CCK)
Détention brevets de la classe C07K 14/595
Brevets de cette classe: 32
Historique des publications depuis 10 ans
|
1
|
3
|
3
|
2
|
3
|
2
|
1
|
0
|
1
|
0
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Zealand Pharma A/S | 211 |
5 |
| Paul Scherrer Institut | 299 |
4 |
| Waratah Pharmaceuticals Inc. | 19 |
3 |
| Novo Nordisk A/S | 2324 |
2 |
| OncoQR ML GmbH | 4 |
2 |
| Board of Regents, The University of Texas System | 5370 |
1 |
| Adda Biotech Inc. | 6 |
1 |
| Biohit Oyj | 46 |
1 |
| Cancer Advances, Inc. | 16 |
1 |
| City of Hope | 943 |
1 |
| Compagnie des Peches Saint Malo Sante | 6 |
1 |
| Eli Lilly and Company | 3645 |
1 |
| Museum National D'histoire Naturelle | 36 |
1 |
| OnkoLogix Ltd | 4 |
1 |
| Provincial Health Services Authority | 155 |
1 |
| Public University Corporation Yokohama City University | 219 |
1 |
| The University of British Columbia | 1432 |
1 |
| Aphton Corp | 1 |
1 |
| Ecs-progastrin SA | 8 |
1 |
| Astrimmune Limited | 1 |
1 |
| Autres propriétaires | 1 |